Canaccord initiated coverage of Kymera Therapeutics (KYMR) with a Buy rating and $106 price target The firm views Kymera as one of the “more cutting-edge technology companies” developing drugs within the immunology and inflammation space. KT-621 is being investigated in two Phase IIb trials for the indications of atopic dermatitis and eosinophilic asthma, the analyst tells investors in a research note. Canaccord projects an approval in atopic dermatitis in 2030 with sales and royalty revenue of $6.5B in 2036. It also expects a launch in asthma in 2031 with sales and royalty revenue of $3.9B in 2036.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
- Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
- FDA grants fast track designation to Kymera Therapeutics KT-621
- Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
- Kymera Therapeutics announces Gilead option exercise to license KT-200